Board summary
Key figures
38,654
Registered population
59.3% aged 18–64
21.7%
Aged 65+
ICB 19.0% · England 17.9%
7.8%
Ethnic minority (non-White)
3.8% Asian · England 9.6%
2.7%
In IMD quintile 1
ICB 31.9% · England 21.0%
~998
Core20 residents (est.)
Resident basis; registered basis ~1,110 · see page 3
5,959
Hypertension register
+8.51% in 3 yrs · England +5.60%
355
SMI register
9.4% of Cheshire West and Chester (LAD)'s
505
COPD register
Reviews +4.45% in 3 yrs
Forecast to 2030
7,209
Hypertension patients, 2030
+1,250 on today
79.1%
QRISK ≥20% on statins, 2030
+7.08pp over 3 yrs
5.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual review coverage trails benchmarks.
Only 56.3% of the 2,583 asthma patients had a review, trailing England (65.7%) and leaving about 1,100 patients unreviewed.
Recorded COPD prevalence sits below comparators.
Crude COPD prevalence is 1.3% versus 2.1% locally and 1.9% nationally (-2.5% three-year change; +227 to +324 benchmark gap), which may reflect unverified under-detection.
Lipid therapy uptake grew faster than England.
Lipid-lowering therapy for patients with QRISK ≥ 20% rose +12.9% over 2023 to 2025 (England +6.2%), reaching 62.1% coverage.
Population, age and ethnicity
Patients aged 65+ comprise 21.7% of registered list, above England's 17.9%
Chester East PCN serves 38,654 registered patients across its member practices, with an older age profile: 21.7% (8,404 patients) are aged 65+, above Cheshire West and Chester (LAD) (20.3%), NHS Cheshire and Merseyside Integrated Care Board (19.0%) and England (17.9%). Working-age adults (18–64) comprise 59.3% and children (0–17) 19.0%. Census estimates for associated resident areas indicate 92.2% are White, below the LAD (95.3%) and ICB (93.0%) but above England (81.1%), with an ethnic minority share of 7.8%. Registered patient counts and Census resident estimates use different population bases.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 2.7% overall and reaches 7.4% at Park Medical Centre
The PCN records an average IMD decile of 7.8 and a Core20 share of 2.7%, below Cheshire West and Chester (15.7%), the ICB (31.9%), and England (21.0%). Across practices, Core20 share spans a 7.4 pp range, from 7.4% at Park Medical Centre (736 estimated patients) to 0.0% at Heath Lane Medical Centre. Practice estimates sum to 1,110 patients (2.9% weighted share) alongside 998 resident Core20 individuals; these distinct bases cannot be combined. Prioritise targeted outreach and service access at Park Medical Centre where deprivation is concentrated.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
355
SMI register
0.91% recorded prevalence
151
Learning disability register
0.39% recorded prevalence
26
Care homes, 1,184 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
The PCN records 355 patients on its severe mental illness register (0.9%) and 151 with learning disabilities (0.4%, below England's 0.6%), alongside 26 catchment care homes with 1,184 beds. Borough figures (9.6% unpaid carers, 29 rough sleepers) are local authority estimates and cannot be extrapolated directly. Lower recorded learning disability prevalence may reflect coding differences or age structure, which register audits would test.
Severe mental illness: physical health checks
For SMI checks, 80.5% had blood pressure recorded (England 83.4%) and 78.8% had BMI checked (England 82.1%). Smoking cessation support fell 13.7 pp (England +0.1 pp) to 82.9% (England 94.2%), dropping to 51.2% at Park Medical Centre.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,959
Hypertension register
+8.51%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
+2.04pp
BP control, under 80
≤140/90 · −0.25pp aged 80+
+1,250
More patients by 2030
Forecast 7,209 (17.98%)
Hypertension case-finding and control
Chester East PCN records 5,959 hypertension patients (15.3% prevalence), in line with England (15.2%) but below Cheshire West and Chester (LAD) (17.0%) and the ICB (16.8%). Although 88.7% of patients had a recent blood pressure reading (England 90.0%), treatment to target reaches 66.8%, below England (70.3%), the borough (68.9%), and the ICB (69.1%). For patients aged under 80, control sits at 63.4% (England 67.8%, ICB 66.4%), falling to 59.3% at Heath Lane Medical Centre. Blood pressure control below England despite strong testing reach suggests prioritising medication titration and reviews could help close control gaps.
Lipids and statins
For patients with QRISK ≥ 20%, 62.1% receive lipid-lowering therapy, trailing England (63.6%) and Cheshire West and Chester (LAD) (63.8%) despite a +12.9% three-year increase (England +6.2%). Fewer high-risk patients receive lipid-lowering therapy than national rates suggest, so a recall audit could help address primary prevention gaps.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 52,558 | £1.60 | £1.71 | £1.86 | £84,093 |
| Cardiovascular (all), 2025 | 75,621 | £6.26 | £4.37 | £3.33 | £473,387 |
In 2026, lipid-regulating drugs cost £1.60 per item across 52,558 items, below England (£1.86) and the ICB (£1.71) but above Cheshire West and Chester (LAD) (£1.44), spending £13,665 less than at England's unit cost. Unit costs below England may provide scope to expand therapy to untreated high-risk patients.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.95%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.54%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.3% (505 patients), falling 2.5% over 2023 to 2025 (England +2.6%), below Cheshire West and Chester (LAD) (2.1%) and England (1.9%), with a benchmark gap of +227 to +324 patients. COPD reviews reach 72.3% (England 76.4%). Asthma prevalence is 7.0% (2,583 patients), but reviews cover 56.3% (England 65.7%), leaving about 1,100 patients without a recorded review. For asthma patients aged 6–19, second-hand smoke status recording is 63.4% (England 78.8%).
Cancer register and children's immunisation
The cancer register records 1,741 patients (4.5% prevalence vs England 3.8%), rising +13.2% over 2023 to 2025 (England +9.0%). In childhood immunisations in Q1 2025/26, 12-month 6-in-1 coverage is 90.1% (below the 95.0% target by 4.9 pp; England 91.0%) and 24-month MMR dose 1 is 92.9%. By age 5, MMR dose 1 reaches 98.8% and dose 2 reaches 97.6% (a 1.2 pp dose difference).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In NHS Cheshire and Merseyside ICB, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2 in 2022, below the 75.0% national ambition and requiring about 2,640 extra early diagnoses annually, with staged cancers representing 72.8% of registered cancers (these data describe the wider ICB system, not PCN performance). Chester East PCN records 1,741 cancer patients (4.5% prevalence), rising +13.2% over 2023 to 2025 (England +9.0%). PCN cervical screening coverage is 73.5% (England 66.8%), but Park Medical Centre records 69.3% after a -6.7% three-year change. Prioritising cervical screening recall where uptake lags could help protect early cancer detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Countess of Chester Hospital NHS Foundation Trust met the cancer 28-day faster diagnosis standard at 87.4%, outperforming North Cheshire and Mersey NHS Foundation Trust (80.2%), Liverpool University Hospitals NHS Foundation Trust (75.5%), the ICB (77.2%) and England (79.3%). However, its 62-day standard reached 83.3% against the 85.0% target (ICB 76.2%, England 71.2%), and its 31-day treatment standard was 93.5% against the 96.0% standard. Diagnostic six-week waits reached 26.4% for colonoscopy and 11.3% for MRI. These provider-level measures reflect system capacity rather than PCN performance.
| Pathways within standard (%) | Countess of Chester | North Cheshire and Mersey | Liverpool | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 87.37 | 80.21 | 75.47 | 77.25 | 79.32 |
| 31-day treatment (96%) | 93.48 | 98.17 | 90.51 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.28 | 83.67 | 73.26 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Countess of Chester | North Cheshire and Mersey | Liverpool | England |
|---|---|---|---|---|
| MRI | 11.26 | 0.53 | 6.42 | 21.40 |
| CT | 4.18 | 2.32 | 0.71 | 9.92 |
| Echocardiography | 31.44 | 28.04 | 12.55 | 28.48 |
| Colonoscopy | 26.44 | 15.98 | 33.14 | 30.83 |
| Gastroscopy | 27.52 | 20.24 | 44.99 | 29.02 |
| All 15 DM01 tests | 20.16 | 6.34 | 11.50 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In Cheshire West and Chester, community services recorded 47,655 total contacts in June 2026 (provisional), with adults aged 65+ accounting for 25,095 contacts or 52.7% of the total activity. This upper-tier authority volume highlights substantial local community demand among older residents, although the figures represent borough residents rather than PCN-specific activity.
Practice variation and patient experience
Phone access spans 27.9 pp and vaccination achievement ranges 53.0 pp across practices
In 2025/26, Park Medical Centre recorded 94.0% overall QOF achievement. Heath Lane Medical Centre recorded 99.8% overall QOF achievement. The England comparator was 92.5%. For QOF vaccination and immunisation-domain achievement, Park Medical Centre achieved 47.0%, while Heath Lane Medical Centre achieved 100.0%, showing a 53.0 pp practice range against the England figure of 55.2%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Boughton Medical | 115 | 1.6 | 68.2% | 79.7% | 91.5% |
| Upton Village | 110 | 2.0 | 70.5% | 73.2% | 86.5% |
| Park | 103 | 7.4 | 42.7% | 75.1% | 75.0% |
| Heath Lane | 96 | 0.0 | 54.1% | 65.3% | 69.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Preventive gains in diabetes and mental health contrast with trailing reviews and registers
Over 2023 to 2025, Chester East PCN recorded three-year increases in diabetes control without frailty (+9.2% relative vs England +4.4%; 59.1% vs England 57.4%) and severe mental illness BMI recording (+10.5 pp vs England +5.1 pp). Conversely, smoking cessation support fell 13.7 pp (England +0.1 pp) to 82.9% (England 94.2%), and heart failure reviews fell 4.2% (England +8.7%) to 72.1% (England 78.5%). Review workflows for chronic cardiovascular conditions require structured clinical prioritisation across practices.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Smoking support (SMI)
Heart failure reviews
COPD register
BP control, 80+
Hypertension treated to target
QRISK statin treatment
BMI record (SMI)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (1,184 beds) | n/a | Schools (catchment) | 56 | n/a |
| Children's centres | 1 | 15 | Places of worship | 36 | 231 |
| Libraries | 2 | 16 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 8 | 70 |
| Primary academies | 8 | 46 | Special schools | 2 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
56.3% of 2,583 asthma patients had a review in the last 12 months, below the LAD (60.0%), ICB (62.3%) and England (65.7%), leaving 1,129 (about 1,100) unreviewed. For discussion: run structured recall using a single review template and trial flexible slots alongside inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD case-finding and spirometry audit
COPD prevalence is 1.3% (505 patients) after a -2.5% change (2023 to 2025), below England (1.9%, +2.6%) and the LAD (2.1%, +2.0%), a +227 to +324 patient gap. For discussion: search for smokers or ex-smokers with repeated respiratory prescribing lacking a COPD code, and raise spirometry capacity with system partners. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Hypertension case-finding and titration review
Hypertension prevalence is 15.3% (5,959 patients vs England 15.2%, ICB 16.8%, LAD 17.0%; -72 to +600 gap), while target control is 66.8% (England 70.3%) despite 88.7% BP recording. For discussion: search for repeated raised BP readings lacking a register code and run pharmacist-led titration reviews for uncontrolled patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation support review (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Infant immunisation recall protocol (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD case-finding and spirometry audit (p12) | COPD register · COPD: QOF prevalence · Aged 65+ | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Hypertension case-finding and titration review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
